A Phase 2 interventional study of lisocabtagene maraleucel in Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin and Lymphoma, B-Cell, sponsored by Juno Therapeutics, a Subsidiary of Celgene. Completed at 59 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-20.
Sponsored by Juno Therapeutics, a Subsidiary of Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb — none open to participants now, 1 under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · Bristol-Myers Squibb.
Among the 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb, this one is the 12th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2018, is one of 6 in phase 2, and was the 16th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →None of the 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 11 · Phase 3 2
First in 2007; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 104 across the 19 interventional studies, 20 across the 2 observational. Of the 20 that completed or were terminated, 11 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Juno Therapeutics, a Subsidiary of Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Juno Therapeutics, a Subsidiary of Celgene is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
1 of the studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05688475Bristol-Myers SquibbA Rollover Study of CC-122 | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status, quality of life, and survival.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
This study's enrollment of 74 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Browse Lymphoma, Large B-Cell, Diffuse studies →Juno Therapeutics, a Subsidiary of Celgene is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
First submitted before Juno Therapeutics, Inc. became part of Bristol-Myers Squibb.
Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lisocabtagene maraleucel at a dose of 100×10\^6 CAR+ T cells (50×10\^6 CD8+ CAR+ T cells and 50×10\^6 CD4+ CAR+ T cells), will be given IV in a single-dose schedule on Day 1 (between 2 and 7 days following the completion of lymphodepleting chemotherapy).
Biological: lisocabtagene maraleucel
lisocabtagene maraleucel will be administered as a single dose intravenous (IV) injection
Also known as: JCAR017, liso-cel
Overall Response Rate (ORR)
Overall response rate is the percent of participants with a best overall response (BOR) of either complete response (CR) or partial reasons (PR) based on the Independent Review Committee (IRC) assessment recorded from the time of JCAR017 treatment until disease progression, end of study, the start of another anticancer therapy or JCAR017 retreatment. CR = Score 1, 2, or 3 with or without a residual mass on the positron emission tomography 5-point scale (PET 5PS). A score of 3 in many patients indicates a good prognosis with standard treatment. PR = Score 4 or 5b with reduced uptake compared with baseline and residual mass(es) of any size. PET 5PS = 1- no uptake above background; 2- uptake ≤ mediastinum; 3- uptake \> mediastinum but ≤ liver; 4- uptake moderately \> liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
Time frame: From first dose to disease progression, end of study, the start of another anticancer therapy, or hematopoietic stem cell transplantation (up to approximately 24 months)
Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs)
A TEAE was defined as an adverse event that started any time from initiation of product administration through and including 90 days following product administration. AEs that occurred after the initiation of subsequent anticancer therapy or product retreatment were not considered as product TEAE. AEs are graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (Version 4.03) (NCI CTCAE) guidelines where Grade 3= Severe, Grade 4= Life-threatening, and 5 = Death.
Time frame: From first dose to 90 days following first dose (up to approximately 90 days)
Change From Baseline of Hematology Laboratory Results: Hemoglobin
Change from baseline in Hematology laboratory analysis. Includes Hemoglobin. Baseline is the last observation collected prior to or on the date of product infusion.
Time frame: Baseline and Day 29
Change From Baseline of Hematology Laboratory Results: Leukocytes, Lymphocytes, Neutrophils, Platelets
Change from baseline in Hematology laboratory analysis. Includes Leukocytes, Lymphocytes, Neutrophils, and Platelets. Baseline is the last observation collected prior to or on the date of product infusion.
Time frame: Baseline and Day 29
Change From Baseline of Chemistry Laboratory Results: Albumin
Change from baseline in Chemistry laboratory analysis. Includes Albumin. Baseline is the last observation collected prior to or on the date of product infusion.
Time frame: Baseline and Day 29
Change From Baseline of Chemistry Laboratory Results: Alanine Aminotransferase, Aspartate Aminotransferase, Lactate Dehydrogenase
Change from baseline in Chemistry laboratory analysis. Includes Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase. Baseline is the last observation collected prior to or on the date of product infusion.
Time frame: Baseline and Day 29
Change From Baseline of Chemistry Laboratory Results: Bilirubin, Creatinine, Direct Bilirubin, Urate
Change from baseline in Chemistry laboratory analysis. Includes Bilirubin, Creatinine, Direct Bilirubin, and Urate. Baseline is the last observation collected prior to or on the date of product infusion.
Time frame: Baseline and Day 29
Change From Baseline of Chemistry Laboratory Results: Calcium Corrected, Magnesium, Phosphate, Potassium, Sodium
Change from baseline in Chemistry laboratory analysis. Includes Calcium Corrected, Magnesium, Phosphate, Potassium, and Sodium. Baseline is the last observation collected prior to or on the date of product infusion.
Time frame: Baseline and Day 29
Complete Response (CR) Rate
Complete response rate (CRR) was defined as the percent of participants with a best overall response (BOR) of complete response (CR) based on the Independent Review Committee (IRC) assessment recorded from the time of JCAR017 treatment until disease progression, end of study, the start of another anticancer therapy or JCAR017 retreatment. CR = Score 1, 2, or 3 with or without a residual mass on the positron emission tomography 5-point scale (PET 5PS). A score of 3 in many patients indicates a good prognosis with standard treatment. PET 5PS = 1- no uptake above background; 2- uptake ≤ mediastinum; 3- uptake \> mediastinum but ≤ liver; 4- uptake moderately \> liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
Time frame: From first dose to disease progression, end of study, the start of another anticancer therapy, or hematopoietic stem cell transplant (up to approximately 24 months)
Duration of Response (DOR)
Duration of response (DOR) is defined as the time from first complete response(CR) or partial response (PR) to progressive disease (PD) or death, whichever occurred first. CR = Score 1, 2, or 3 on the positron emission tomography 5-point scale (PET 5PS). A score of 3 indicates a good prognosis with standard treatment. PR = Score 4 or 5b with reduced uptake compared with baseline and residual mass(es) of any size. PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1-no uptake above background; 2-uptake ≤ mediastinum; 3-uptake \> mediastinum but ≤ liver; 4-uptake moderately \> liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
Time frame: From first dose to up to approximately 24 months
Duration of Response (DOR) in Participants With Complete Response (CR)
DOR for participants with a best overall response of CR was defined as the time from documentation of first response (or CR) to progressive disease (PD) or death, whichever occurred first. The first documentation of CR/PR is the latest of all dates of required measurements to establish the response. The progression date is the earliest date of all assessments that led to a response assessment of PD. CR = Score 1, 2, or 3 on the positron emission tomography 5-point scale (PET 5PS). A score of 3 indicates a good prognosis with standard treatment. PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1-no uptake above background; 2-uptake ≤ mediastinum; 3-uptake \> mediastinum but ≤ liver; 4-uptake moderately \> liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
Time frame: From first dose to up to approximately 24 months
Progression-Free Survival (PFS)
PFS is defined as the time from JCAR017 infusion to progressive disease (PD) or death. Kaplan-Meier (KM) methodology will be used to analyze PFS. PD = Score 4 or 5b on the positron emission tomography 5-point scale (PET 5PS) with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1- no uptake above background; 2- uptake ≤ mediastinum; 3- uptake \> mediastinum but ≤ liver; 4- uptake moderately \> liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
Time frame: From first dose to progressive disease (PD) or death (up to approximately 24 months)
Event-Free Survival (EFS)
EFS is defined as the time from JCAR017 infusion to the earliest of the following events: death from any cause, progressive disease (PD), or starting a new anticancer therapy. Kaplan-Meier (KM) methodology will be used to analyze EFS. PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1-no uptake above background; 2-uptake ≤ mediastinum; 3-uptake \> mediastinum but ≤ liver; 4-uptake moderately \> liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
Time frame: From first dose to death from any cause, progressive disease (PD), or starting a new anticancer therapy (up to approximately 24 months)
Overall Survival (OS)
OS is defined as the time from JCAR017 infusion to the date of death. Kaplan-Meier (KM) methodology will be used to analyze OS.
Time frame: From first dose to date of death (up to approximately 24 months)
PK Parameters of JCAR017 in Blood as Assessed by qPCR: Cmax
Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR). Cmax = Maximum observed blood concentration.
Time frame: From first dose to up to 24 months
PK Parameters of JCAR017 in Blood as Assessed by qPCR: Tmax
Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR). Tmax = Time of maximum observed blood concentration.
Time frame: From first dose to up to 24 months
PK Parameters of JCAR017 in Blood as Assessed by qPCR: AUC (0-28)
Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR). AUC (0-28) = Area under the curve for concentration.
Time frame: From first dose to up to 24 months
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Fatigue Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
Time frame: Baseline and Day 29
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Physical Functioning Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
Time frame: Baseline and Day 29
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Cognitive Functioning Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
Time frame: Baseline and Day 29
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Global Health/QoL Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
Time frame: Baseline and Day 29
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Role Functioning Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
Time frame: Baseline and Day 29
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Emotional Functioning Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
Time frame: Baseline and Day 29
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Social Functioning Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
Time frame: Baseline and Day 29
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Pain Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
Time frame: Baseline and Day 29
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Nausea/Vomiting Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
Time frame: Baseline and Day 29
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Constipation Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
Time frame: Baseline and Day 29
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Diarrhea Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
Time frame: Baseline and Day 29
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Insomnia Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
Time frame: Baseline and Day 29
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Dyspnea Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
Time frame: Baseline and Day 29
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Appetite Loss Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
Time frame: Baseline and Day 29
Mean Score in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) Financial Difficulties Subscale
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
Time frame: Baseline and Day 29
Health-Related Quality of Life (HRQoL) Assessed by the FACT-Lym Subscale
The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) consists of the FACT-General scale and a 15-item lymphoma-specific additional concerns subscale (LYM). This scale addresses symptoms and functional limitations that are important to lymphoma patients. The LYM items are scored on a 0 ("Not at all") to 4 ("Very much") response scale. Items are aggregated to a single score on a 0-60 scale.
Time frame: Baseline and Day 29
Health-Related Quality of Life (HRQoL) Assessed by the EuroQol Instrument EQ-5D-5L
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-5L health states ranged from -.594 for the worst (55555) to 1 for the best (11111) for UK value set with an optimal health state is assigned a score of 1.00, death is assigned a score of 0.00 and negative values representing values as worse than dead. A change of .08 is considered to be a clinically meaningful change in health utility.
Time frame: Baseline and Day 29
Numbers of Intensive Care Unit (ICU) Inpatient Days
The numbers of ICU inpatient days.
Time frame: From first dose after JCAR017 infusion to up to approximately 24 months
Numbers of Non-intensive Care Unit (ICU) Inpatient Days
Number of non-ICU inpatient days.
Time frame: From first dose after JCAR017 infusion to up to approximately 24 months
The Number of Participants That Were Hospitalized For Adverse Events, Prophylaxis, Other
Length of hospitalization stay was reported for up to 24 months post liso-cel infusion. Reasons for hospitalization include adverse events, prophylaxis, and other. Adverse events were reported for up to 90 days post liso-cel infusion.
Time frame: From first dose after JCAR017 infusion to up to approximately 24 months
| Milestone | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Started | 74 |
| Completed | 63 |
| Not completed | 11 |
| Withdrew: Other reasons | 1 |
| Withdrew: No longer meets eligibility criteria | 4 |
| Withdrew: Disease-related complications | 1 |
| Withdrew: Death | 5 |
| Milestone | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Started | 63 |
| Received jcar017 | 61 |
| Received nonconforming product | 1 |
| Did not receive either jar017 or nonconforming product | 1 |
| Completed | 30 |
| Not completed | 33 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Other reasons | 1 |
| Withdrew: Death | 23 |
| Withdrew: Did not receive either jar017 or nonconforming product | 1 |
| Withdrew: Received nonconforming product | 1 |
Overall response rate is the percent of participants with a best overall response (BOR) of either complete response (CR) or partial reasons (PR) based on the Independent Review Committee (IRC) assessment recorded from the time of JCAR017 treatment until disease progression, end of study, the start of another anticancer therapy or JCAR017 retreatment. CR = Score 1, 2, or 3 with or without a residual mass on the positron emission tomography 5-point scale (PET 5PS). A score of 3 in many patients indicates a good prognosis with standard treatment. PR = Score 4 or 5b with reduced uptake compared with baseline and residual mass(es) of any size. PET 5PS = 1- no uptake above background; 2- uptake ≤ mediastinum; 3- uptake \> mediastinum but ≤ liver; 4- uptake moderately \> liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
| Percent of Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Overall Response Rate (ORR) | 80.3 (68.2 to 89.4) |
A TEAE was defined as an adverse event that started any time from initiation of product administration through and including 90 days following product administration. AEs that occurred after the initiation of subsequent anticancer therapy or product retreatment were not considered as product TEAE. AEs are graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (Version 4.03) (NCI CTCAE) guidelines where Grade 3= Severe, Grade 4= Life-threatening, and 5 = Death.
| Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Participants with any TEAE | 59 |
| Participants with any serious TEAEs | 20 |
| Participants with any Grade ≥ 3 TEAEs | 48 |
| Participants with any product-related TEAE | 48 |
Change from baseline in Hematology laboratory analysis. Includes Hemoglobin. Baseline is the last observation collected prior to or on the date of product infusion.
| g/L | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Change From Baseline of Hematology Laboratory Results: Hemoglobin | 1.9 ± 10.05 |
Change from baseline in Hematology laboratory analysis. Includes Leukocytes, Lymphocytes, Neutrophils, and Platelets. Baseline is the last observation collected prior to or on the date of product infusion.
| 10^9 cells/L | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Leukocytes | 0.921 ± 3.8562 |
| Lymphocytes | 0.537 ± 0.5953 |
| Neutrophils | -0.216 ± 3.4010 |
| Platelets | -61.6 ± 96.55 |
Change from baseline in Chemistry laboratory analysis. Includes Albumin. Baseline is the last observation collected prior to or on the date of product infusion.
| g/L | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Change From Baseline of Chemistry Laboratory Results: Albumin | 3.05 ± 3.866 |
Change from baseline in Chemistry laboratory analysis. Includes Alanine Aminotransferase, Aspartate Aminotransferase, and Lactate Dehydrogenase. Baseline is the last observation collected prior to or on the date of product infusion.
| U/L | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Alanine Aminotransferase | 4.6 ± 16.42 |
| Aspartate Aminotransferase | -3.9 ± 21.22 |
| Lactate Dehydrogenase | -138.2 ± 339.82 |
Change from baseline in Chemistry laboratory analysis. Includes Bilirubin, Creatinine, Direct Bilirubin, and Urate. Baseline is the last observation collected prior to or on the date of product infusion.
| umol/L | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Bilirubin | -0.1741 ± 6.36075 |
| Creatinine | 5.8734 ± 21.32985 |
| Direct Bilirubin | 0.0306 ± 2.35650 |
| Urate | 5.7897 ± 93.90174 |
Change from baseline in Chemistry laboratory analysis. Includes Calcium Corrected, Magnesium, Phosphate, Potassium, and Sodium. Baseline is the last observation collected prior to or on the date of product infusion.
| mmol/L | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Calcium Corrected | -0.0261 ± 0.12183 |
| Magnesium | -0.0209 ± 0.09292 |
| Phosphate | 0.0479 ± 0.22624 |
| Potassium | -0.05 ± 0.426 |
| Sodium | 1.0 ± 3.37 |
Complete response rate (CRR) was defined as the percent of participants with a best overall response (BOR) of complete response (CR) based on the Independent Review Committee (IRC) assessment recorded from the time of JCAR017 treatment until disease progression, end of study, the start of another anticancer therapy or JCAR017 retreatment. CR = Score 1, 2, or 3 with or without a residual mass on the positron emission tomography 5-point scale (PET 5PS). A score of 3 in many patients indicates a good prognosis with standard treatment. PET 5PS = 1- no uptake above background; 2- uptake ≤ mediastinum; 3- uptake \> mediastinum but ≤ liver; 4- uptake moderately \> liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
| Percent of Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Complete Response (CR) Rate | 54.1 (40.8 to 66.9) |
Duration of response (DOR) is defined as the time from first complete response(CR) or partial response (PR) to progressive disease (PD) or death, whichever occurred first. CR = Score 1, 2, or 3 on the positron emission tomography 5-point scale (PET 5PS). A score of 3 indicates a good prognosis with standard treatment. PR = Score 4 or 5b with reduced uptake compared with baseline and residual mass(es) of any size. PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1-no uptake above background; 2-uptake ≤ mediastinum; 3-uptake \> mediastinum but ≤ liver; 4-uptake moderately \> liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
| Months | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Duration of Response (DOR) | 23.26 (6.24 to NA) |
DOR for participants with a best overall response of CR was defined as the time from documentation of first response (or CR) to progressive disease (PD) or death, whichever occurred first. The first documentation of CR/PR is the latest of all dates of required measurements to establish the response. The progression date is the earliest date of all assessments that led to a response assessment of PD. CR = Score 1, 2, or 3 on the positron emission tomography 5-point scale (PET 5PS). A score of 3 indicates a good prognosis with standard treatment. PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1-no uptake above background; 2-uptake ≤ mediastinum; 3-uptake \> mediastinum but ≤ liver; 4-uptake moderately \> liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
| Months | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Duration of Response (DOR) in Participants With Complete Response (CR) | NA (21.65 to NA) |
PFS is defined as the time from JCAR017 infusion to progressive disease (PD) or death. Kaplan-Meier (KM) methodology will be used to analyze PFS. PD = Score 4 or 5b on the positron emission tomography 5-point scale (PET 5PS) with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1- no uptake above background; 2- uptake ≤ mediastinum; 3- uptake \> mediastinum but ≤ liver; 4- uptake moderately \> liver; 5- uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
| Months | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Progression-Free Survival (PFS) | 9.03 (4.17 to NA) |
EFS is defined as the time from JCAR017 infusion to the earliest of the following events: death from any cause, progressive disease (PD), or starting a new anticancer therapy. Kaplan-Meier (KM) methodology will be used to analyze EFS. PD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment. PET 5PS = 1-no uptake above background; 2-uptake ≤ mediastinum; 3-uptake \> mediastinum but ≤ liver; 4-uptake moderately \> liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.
| Months | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Event-Free Survival (EFS) | 7.23 (3.22 to 24.28) |
OS is defined as the time from JCAR017 infusion to the date of death. Kaplan-Meier (KM) methodology will be used to analyze OS.
| Months | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Overall Survival (OS) | NA (16.33 to NA) |
Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR). Cmax = Maximum observed blood concentration.
| copies/μg | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| PK Parameters of JCAR017 in Blood as Assessed by qPCR: Cmax | 22516.3 ± 237.4 |
Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR). Tmax = Time of maximum observed blood concentration.
| Day | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| PK Parameters of JCAR017 in Blood as Assessed by qPCR: Tmax | 10.0 (6 to 22) |
Pharmacokinetic (PK) analyses were based on quantitative polymerase chain reaction (qPCR). AUC (0-28) = Area under the curve for concentration.
| day*copies/ug | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| PK Parameters of JCAR017 in Blood as Assessed by qPCR: AUC (0-28) | 178631.0 ± 228.3 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 36.706 ± 27.6193 |
| Day 29 | 37.731 ± 19.9473 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 77.827 ± 24.2897 |
| Day 29 | 71.667 ± 23.8395 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 83.333 ± 17.4078 |
| Day 29 | 88.194 ± 14.9698 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 66.815 ± 25.5491 |
| Day 29 | 72.049 ± 18.7910 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 77.083 ± 30.4117 |
| Day 29 | 69.792 ± 28.0695 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 81.061 ± 17.1575 |
| Day 29 | 86.806 ± 13.4077 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 74.702 ± 26.3985 |
| Day 29 | 72.917 ± 25.8713 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 26.488 ± 29.2631 |
| Day 29 | 13.542 ± 22.4546 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 5.655 ± 10.6727 |
| Day 29 | 6.250 ± 14.4338 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 11.905 ± 23.2931 |
| Day 29 | 6.944 ± 13.6805 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 13.690 ± 21.8135 |
| Day 29 | 11.806 ± 21.1821 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 25.595 ± 27.7005 |
| Day 29 | 20.139 ± 27.2798 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 10.714 ± 21.1843 |
| Day 29 | 13.194 ± 17.8510 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Symptom scale/item higher score represents a high level of symptomatic problem.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 18.788 ± 29.9270 |
| Day 29 | 22.222 ± 28.6277 |
* Health Related Quality of Life (HRQoL) was assessed using the EORTC QLQ-C30 questionnaire. * The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. * All of the scales and single-item measures range in score from 0 to 100. A 10-point change in the scoring is considered to be a meaningful change in HRQoL. * Functional scale and global health status/HRQoL higher scale score represents a higher level of well-being and better ability of daily functioning.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 13.690 ± 22.7208 |
| Day 29 | 14.583 ± 21.6421 |
The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) consists of the FACT-General scale and a 15-item lymphoma-specific additional concerns subscale (LYM). This scale addresses symptoms and functional limitations that are important to lymphoma patients. The LYM items are scored on a 0 ("Not at all") to 4 ("Very much") response scale. Items are aggregated to a single score on a 0-60 scale.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 44.22 ± 8.804 |
| Day 29 | 48.71 ± 6.447 |
The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. These health states are converted to a single index value using the crosswalk method to the EQ-5D-3L value set from the United Kingdom (UK). The EQ-5D-5L health states ranged from -.594 for the worst (55555) to 1 for the best (11111) for UK value set with an optimal health state is assigned a score of 1.00, death is assigned a score of 0.00 and negative values representing values as worse than dead. A change of .08 is considered to be a clinically meaningful change in health utility.
| Scores on a scale | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Baseline | 0.7378 ± 0.23190 |
| Day 29 | 0.7719 ± 0.20651 |
The numbers of ICU inpatient days.
| Day | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Numbers of Intensive Care Unit (ICU) Inpatient Days | 0.0 (0 to 30) |
Number of non-ICU inpatient days.
| Day | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Numbers of Non-intensive Care Unit (ICU) Inpatient Days | 14.0 (3 to 34) |
Length of hospitalization stay was reported for up to 24 months post liso-cel infusion. Reasons for hospitalization include adverse events, prophylaxis, and other. Adverse events were reported for up to 90 days post liso-cel infusion.
| Participants | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Adverse Event | 2 |
| Prophylaxis for CAR T-cell administration | 36 |
| Other | 3 |
Collected over Participants were assessed for all-cause mortality from the first participant undergoing leukapheresis until study completion (up to approximately 52 months). SAEs and Other AEs were assessed from the first participant undergoing leukapheresis to 90 days following the first participant undergoing leukapheresis (up to approximately 90 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lisocabtagene Maraleucel (JCAR017) | 30/74 (40.5%) | 20/61 (32.8%) | 59/61 (96.7%) |
| Event | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Cytokine release syndromeImmune system disorders | 8/61 |
| Confusional statePsychiatric disorders | 3/61 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 2/61 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 2/61 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/61 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/61 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 1/61 |
| Obstruction gastricGastrointestinal disorders | 1/61 |
| BacteraemiaInfections and infestations | 1/61 |
| COVID-19Infections and infestations | 1/61 |
| Event | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 31/61 |
| FatigueGeneral disorders | 24/61 |
| AnaemiaBlood and lymphatic system disorders | 19/61 |
| ThrombocytopeniaBlood and lymphatic system disorders | 18/61 |
| NauseaGastrointestinal disorders | 15/61 |
| Cytokine release syndromeImmune system disorders | 15/61 |
| LeukopeniaBlood and lymphatic system disorders | 14/61 |
| HypokalaemiaMetabolism and nutrition disorders | 11/61 |
| HypomagnesaemiaMetabolism and nutrition disorders | 11/61 |
| DiarrhoeaGastrointestinal disorders | 10/61 |
74 participants were leukapheresed.
| Age, Continuous(Years) | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Mean | 72.8 ± 6.57 |
| Age, Customized(Participants) | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| < 65 years | 8 |
| >= 65 to < 70 years | 7 |
| >= 70 to < 75 years | 27 |
| >= 75 years | 32 |
| Sex: Female, Male(Participants) | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Female | 29 |
| Male | 45 |
| Ethnicity (NIH/OMB)(Participants) | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 64 |
| Unknown or Not Reported | 9 |
| Race (NIH/OMB)(Participants) | Lisocabtagene Maraleucel (JCAR017) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 64 |
| More than one race | 0 |
| Unknown or Not Reported | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in Sep 2021, 37 months.
Results were first posted in Dec 2022, 1 year 3 months after primary completion.
Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 37 months is close to that.
Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisocabtagene maraleucel
Lymphoma, Large B-Cell, Diffuse →
Juno Therapeutics, a Subsidiary of Celgene →